
Subdued dollar firms after ECB leaves rates alone; tariffs and Fed in focus
The greenback showed fractional gains late in a subdued U.S. session, with investors girding for a busy news flow next week.
The European Central Bank left its policy rate at 2 per cent, as expected, on Thursday, taking a break after a year of policy easing to wait for clarity over Europe's future trade relations with the United States.
"The view that the ECB is probably on hold here is probably gaining a bit more traction. We've trimmed expectations for the cuts in September to certainly less than 50/50," said Shaun Osborne, chief foreign exchange strategist at Scotiabank in Toronto.
The Japanese central bank's deputy governor, Shinichi Uchida, said Tuesday's trade deal with Washington had reduced economic uncertainty, comments that fuelled optimism in the market about the potential resumption of interest rate hikes.
Analysts believe the yen will face persistent headwinds after Sunday's upper house election, with the opposition considering a no-confidence motion.
The European Union is nearing a deal that would impose a broad 15 per cent tariff on EU goods, diplomats said. The rate, which could also extend to cars, would mirror the framework agreement the United States struck with Japan.
"The ECB faces a challenge that is quantitatively different from the BoJ's," said Thierry Wizman, global forex and rates strategist at Macquarie Group.
"The euro has appreciated by far more than the JPY so far in 2025, meaning that the disinflationary impulse from U.S. import tariffs may be greater in the EU than in Japan, or the ECB may suspect as much," he added.
PMI data showed fragility in France following budget-cut proposals there, but also resilience in Germany and other parts of the euro zone.
Data showed that German business activity continued to grow marginally in July.
"As of now, there has been very little tariff impact on the hard data," said Mohit Kumar, economist at Jefferies.
ECONOMIC FALLOUT
Meanwhile, risk assets rallied as the trade deals eased fears over the economic fallout of a global trade war.
Next week the Federal Open Market Committee meets and is expected to leave rates where they are as policy makers wait for the expected impact from tariffs on inflation and growth to show up. Traders are now pricing in a 60 per cent chance of a quarter point September rate cut, according to CME's FedWatch tool.
A number of U.S. employment releases next week culminate with Friday's big June payrolls report, while the July Personal Consumption Expenditures Price Index and the first revision to 2nd quarter Gross Domestic Product could also move markets.
"A lot of event risk next week and not just from the Fed, we've got a lot of data next week as well, so that's probably going to shape expectations to some extent for September," Osborne said.
The euro was last off 0.03 per cent $1.1766, near the $1.1830 high from earlier this month, which marked its strongest level in more than three years.
Against the yen, the dollar was 0.27 per cent firmer at 146.88, having hit a two-week low earlier in the session at 145.86.
Olivier Korber, forex strategist at Societe Generale, expects the yen to strengthen further, citing support from the trade deal and prospects for higher interest rates.
Japanese Prime Minister Shigeru Ishiba denied on Wednesday he had decided to quit after a source and media reports said he planned to announce his resignation to take responsibility for a bruising upper house election defeat.
Currencies mostly shrugged off news that U.S. President Donald Trump, a vocal critic of Federal Reserve Chair Jerome Powell, will visit the central bank on Thursday, a surprise move that escalates tensions between the administration and the Fed.
The dollar index, which measures the greenback against a basket of six currencies including the euro and yen, rose 0.17 per cent to 97.36.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Straits Times
13 hours ago
- Straits Times
Pfizer and BioNTech lose UK court appeal over Covid-19 jab
Sign up now: Get ST's newsletters delivered to your inbox Moderna has accused Pfizer and BioNTech of violating its intellectual property rights with regard to mRNA technology. LONDON - US pharmaceutical giant Pfizer and German firm BioNTech lost on Aug 1 a court appeal in the latest step of a multi-million pound battle against US rival Moderna over the Covid-19 vaccine. The Appeals Court in London upheld an earlier UK court decision in the long-running battle between the global pharma firms. It found that one of the European patents held by Moderna was invalid, but that a second one had been broken by Pfizer and its German partner BioNTech. 'The judge made no error of law or principle' in the ruling handed down in July 2024, the Appeal Court judges wrote Friday, dismissing the appeal brought by the two companies. Pfizer quickly said it will appeal the Aug 1 ruling to Britain's Supreme Court. 'Today's UK Court of Appeal's decision does not change our unwavering stance that this patent is invalid,' Pfizer said in a statement. 'This decision has no immediate impact on Pfizer and BioNTech.' Pfizer and BioNTech had argued that both the patents cited by Moderna were invalid, and neither had been infringed. The Aug 1 decision could have wide implications for other cases involving the huge pharma companies in the United States, Germany, Belgium, the Netherlands and Ireland. Moderna said in a statement it was pleased with the Aug 1 ruling and would 'continue to pursue and enforce its patent rights globally to protect its innovative mRNA technology'. A UK court was told in 2024 the firms had spent £19 million (S$32 million) fighting their legal battles. In 2020, Pfizer and BioNTech's vaccine became the first ever mRNA vaccine approved for widespread use, and was swiftly deployed to combat the Covid-19 pandemic. Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases. Traditional vaccines contain some form of the dead or inactivated target virus. Since the virus need not be grown in the lab, mRNA vaccines can in theory be developed at scale more quickly than traditional vaccines. In March, a German court in Duesseldorf also found Pfizer and BioNTech had violated a Moderna patent filed between 2010 to 2016 to make their vaccines. It ordered they must provide estimates of how much they had profited from breaking the patent as well as provide 'appropriate compensation'. AFP


CNA
13 hours ago
- CNA
Exclusive-Prosus set to win EU nod for $4.74 billion Just Eat deal, sources say
BRUSSELS :Dutch technology investor Prosus is set to win EU antitrust approval for its 4.1 billion euro ($4.7 billion) bid for Just Eat Takeaway, after agreeing to sell down its stake in Delivery Hero, people with direct knowledge of the matter said. Amsterdam-headquartered Prosus, which is majority owned by South Africa's Naspers, announced the deal in February, banking on its artificial intelligence capability to boost Just Eat Takeaway, Europe's biggest meal delivery company. Prosus last month offered to incrementally sell down its 27.4 per cent stake in Delivery Hero and to give up its board seat to address EU competition concerns, other people familiar with the matter had told Reuters. Delivery Hero and Just Eat Takeaway compete with each other in Austria, Bulgaria, Italy, Poland and Spain. The European Commission, which is now seeking market feedback to Prosus' offer and will decide on the deal by August 11, declined to comment. Prosus also declined to comment. The deal would make Prosus the world's fourth-largest food delivery company after Meituan, DoorDash and Uber, according to ING analysts. Delivery Hero and its Spanish unit Glovo were fined 329 million euros by the EU antitrust watchdog in June for taking part in a cartel which included an agreement to divide up markets among themselves and not to poach each other's employees. ($1 = 0.8658 euros)


CNA
13 hours ago
- CNA
Exclusive-EU antitrust regulators set to clear Prosus, Just Eat Takeaway deal, sources say
BRUSSELS :EU antitrust regulators are set to clear with conditions Dutch technology investor Prosus' 4.1-billion-euro ($4.74 billion) acquisition of Just Eat Takeaway, sources with direct knowledge of the matter said. Amsterdam-headquartered Prosus has proposed incrementally selling down its 27.4 per cent stake in Delivery Hero and giving up its board seat to address EU competition concerns, other people familiar with the matter told Reuters earlier this month. ($1 = 0.8658 euros)